AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05034406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine
Description: 6 mL of 2% lidocaine injected at the trocar insertion site.
Study NCT05034406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Description: 6 mL of 0.5% levobupivacaine injected at the trocar insertion site.
Study NCT04385576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerosol Box
Description: Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
Study NCT04385576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation Box
Description: Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
Study NCT02622555 — intervention group
Intervention type: DRUG
Intervention: Mirabegron
Description: Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine
Study NCT03513926 — intervention group
Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure
Study NCT02236338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of the Incompetent Greater Saphenous Vein
Description: For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
Study NCT02236338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClosureFAST radiofrequency catheter
Study NCT02236338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVLT 980nm diode laser system
Study NCT02659852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: side by side
Description: Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.
Study NCT02659852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stent in stent
Description: After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
Study NCT03093909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
Study NCT04059601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance cholangiography
Description: preoperative MRCP in acute cholecystitis before cholecystectomy
Study NCT04059601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative cholangiography
Description: Intraoperative cholangiography in acute cholecystitis during cholecystectomy
Study NCT00991588 — intervention group
Intervention type: PROCEDURE
Intervention: PCL, posterolateral reconstruction
Description: The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
Study NCT02159716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-meso
Description: CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.
Study NCT01253720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE CALL/Fit4Life
Description: The Fit4Life E intervention will be designed to promote weight loss and subsequent weight loss maintenance through the adoption and maintenance of improved eating, physical activity and sedentary behaviors in at risk for overweight and overweight adolescent survivors of ALL and their parent/guardian. the Fit4Life intervention will incorporate elements of the Chronic Care Model, including frequent phone and mail interactions, an initial in-person encounter to provide encouragement and initial patient-tailored counseling for obesity management, family-centered skill development to achieve healthy behavioral modification via goal setting, self-monitoring, and problem solving.~The Fit4Life intervention includes:~Web-based weight loss program Text and Picture messages Counseling Calls Health Coach
Study NCT03082274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ConfirmMDx
Description: ConfirmMDx is a molecular diagnostic assay which utilizes DNA isolated from biopsy tissues to determine if aberrant DNA methylation is occurring in three genes: GSTP1, RASSF1 and APC. ConfirmMDx is currently available to clinicians for use in cancer-negative extended-core biopsies to determine if occult cancer is present in the prostate.
Study NCT03082274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SelectMDx
Description: SelectMDx for Prostate Cancer is a reverse-transcription PCR (RT-PCR) assay performed on post-DRE, first-void urine specimens from patients with clinical risk factors for prostate cancer, who are being considered for biopsy. The test measures the mRNA levels of the DLX1 and HOXC6 biomarkers, using KLK3 as internal reference gene, to aid in patient selection for prostate biopsy.
Study NCT00760058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ IOL
Description: Replacement of natural crystalline lens in cataract surgery
Study NCT00760058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis® Aspheric intraocular lens
Description: Replacement of natural crystalline lens in cataract surgery
Study NCT00760058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Akreos® MI60 intraocular lens
Description: Replacement of natural crystalline lens in cataract surgery
Study NCT00421174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
Study NCT00421174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus corticosteroid
Description: Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
Study NCT01415466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cresto
Description: tablet, 20mg
Study NCT01415466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmetec
Description: tablet, 40mg
Study NCT01415466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cresto, Olmetec
Description: tablet, 20mg and 40mg
Study NCT02116803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib
Description: Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.
Study NCT02116803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.
Study NCT02966379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implantation
Description: Surgery is standardized in order to have the same procedure for all patients and to preserve a maximum of residual hearing:~* Corticosteroïds (1mg/kg solumedrol) at anesthetic induction ,~* mastoidectomy + posterieur tympanostomy ,~* insertion through round window,~* stop at the first resistance point
Study NCT01287325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333 100 mg twice daily
Study NCT01287325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02614378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air insufflation
Description: modulated air insufflation of the ear canal
Study NCT02614378 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no air will be introduced in the ear canal
Study NCT01245140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alitretinoin
Description: to receive verum (20 patients)
Study NCT01245140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: to receive placebo (10 patients)
Study NCT05528523 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Writing a clinical narrative
Description: The participants had to write a clinical narrative regarding a significant encounter with a patient.
Study NCT04184453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone treated
Description: Deferiprone (25 mg/kg/day) was given to the enrolled patients.
Study NCT02961257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: * Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or~* Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.~* Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.~* Standard cabazitaxel premedication will be used
Study NCT02961257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles
Study NCT02961257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every administration of cabazitaxel
Study NCT04508855 — intervention group
Intervention type: DRUG
Intervention: Low molecular weight heparin
Description: Switch from direct oral anticoagulants to low molecular weight heparin
Study NCT03177720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
Study NCT03177720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem
Description: Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
Study NCT01673022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC Green
Description: IC Green
Study NCT01686139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABMD-MSC
Description: 10-20 x 10\^6 cells/20mL
Study NCT03587766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Drug: fexinidazole (FEXI)
Study NCT03587766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Drug: fexinidazole
Study NCT00421655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazax
Description: Tablets 75,000 SQT and matching placebo. One tablet daily.
Study NCT00421655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazax
Description: Tablets 75,000 SQT and matching placebo. One tablet daily.
Study NCT04377854 — intervention group
Intervention type: OTHER
Intervention: Observation. No intervention per se.
Description: Observation. No intervention (no collection of blood).
Study NCT04377854 — intervention group
Intervention type: OTHER
Intervention: 2) Observation and collection and of blood sample
Description: All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.
Study NCT03637647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing
Description: The CPET involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
Study NCT03953131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT03953131 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-DOTATATE
Description: Given IV
Study NCT03953131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT00258752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT-AST
Description: IPT-AST is a school based group treatment program that focuses on prevention, psychoeducation, and interpersonal skill building.
Study NCT00258752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced IPT-AST
Description: Enhanced IPT-AST entails IPT-AST plus three parent-adolescent sessions.
Study NCT00258752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: School counseling
Description: Usual care consists of standard treatments, including individual counseling with guidance counselor.
Study NCT03902366 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assessment
Description: Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).
Study NCT03902366 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuroimaging
Description: Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
Study NCT03908567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Drug
Description: Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day
Study NCT03908567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Tablet
Description: Oral dosing with tablets 3 times a day
Study NCT03908567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day
Study NCT02926222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is formulated as tablets of 40mg for oral administration.
Study NCT02926222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Lomustine is formulated as tablets of 40mg for oral administration.
Study NCT03797482 — intervention group
Intervention type: PROCEDURE
Intervention: Intra-operative Tumor Tissue Biopsy
Description: The changing pattern of gene expression during surgery has never been studied. This could be an effect of acute hypoxia that sets in the tumour during surgery or could be a surgical response. To study these changes happening in the tumour during surgery, we are taking serial biopsies during surgery, one at the beginning, one midway during surgery and one at the end of surgery. These samples will be snap frozen and stored at -80 deg celsius in biorepository for future analysis.
Study NCT01007110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: Docosahexaenoic Acid (DHA) from algal oil
Study NCT01007110 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT03860766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: An LED blanket with 267 infrared lamps with predetermined doses will be used, given a wavelength of 940nm, for 5 weeks, it will be applied by all extension of the quadriceps and hamstrings bilaterally, just before the force training protocol for the groups intervention or simulation for the sham group. Photochemical or photophysical effects are expected from its application.
Study NCT04429295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT04429295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT04429295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b)
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT04429295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliomyelitis Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT04429295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliomyelitis Vaccine bivalent types 1 and 3
Description: Pharmaceutical form:Oral suspension Route of administration: Oral
Study NCT04429295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rotavirus, live attenuated
Description: Pharmaceutical form:Oral suspension Route of administration: Oral
Study NCT04429295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Rotavirus, live attenuated
Description: Pharmaceutical form:Oral suspension Route of administration: Oral
Study NCT04429295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT04429295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT01609426 — intervention group
Intervention type: GENETIC
Intervention: DNA chip dedicated to the pharmacogenetic of steroids
Description: direct DNA extraction from peripheral blood cells
Study NCT02988323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervicovestibular Physio (CV PT)
Description: See description in CVPT arm
Study NCT02988323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Level Aerobic Exercise (LLAE)
Description: See description in LLAE arm
Study NCT02988323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Combination (LLAE and CV PT)
Description: See description in LLAE and CVPT arm
Study NCT00701324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 811283
Description: dose escalation BI 811283, Arm B (3 weeks)
Study NCT00701324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 811283
Description: dose escalation BI 811283, Arm A (day 1)
Study NCT00701324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 811283
Description: dose escalation BI 811283, Arm A (day 15)
Study NCT01981005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5424802
Description: Single oral doses followed by IV or oral administration of a 14C-labeled tracer